Tempus AI (NASDAQ:TEM) CEO Sells $1,910,168.76 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 33,284 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the sale, the chief executive officer directly owned 167,763 shares of the company’s stock, valued at $9,627,918.57. The trade was a 16.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.
• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50.

Tempus AI Trading Down 5.3%

Tempus AI stock traded down $3.27 during mid-day trading on Friday, hitting $58.23. The company’s stock had a trading volume of 4,354,224 shares, compared to its average volume of 5,957,268. The company has a 50 day moving average of $51.12 and a 200-day moving average of $54.33. The stock has a market cap of $10.46 billion, a PE ratio of -33.85 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same quarter in the previous year, the business earned ($0.24) earnings per share. Tempus AI’s quarterly revenue was up 36.1% on a year-over-year basis. On average, research analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after acquiring an additional 817,014 shares in the last quarter. ARK Investment Management LLC grew its holdings in Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after purchasing an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC acquired a new position in shares of Tempus AI during the fourth quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

TEM has been the subject of a number of recent research reports. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. TD Cowen boosted their price target on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Guggenheim decreased their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Finally, Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $68.54.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.